Key Drivers
- Very high margins
- Strong FCF
- Negative equity
AIAI Summary
AbbVie has shifted from a Humira-dependent cash machine to a multi‑franchise, R&D-driven growth platform whose strong, near-term FCF underpins payouts but whose premium valuation now hinges on continuous high‑conviction execution to replace Humira revenue. Key actionable risk: closely monitor Skyrizi/Rinvoq launch cadence and material deleveraging — if outperformance or meaningful debt reduction doesn't occur, a pipeline or cash shortfall would quickly compress valuation and force payout/strategy changes.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Strong FCF
- •Negative equity
ABBV combines durable high margins and strong free cash flow with strained liquidity, negative shareholders' equity, heavy leverage and rich valuation multiples as of 2025-12-31.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-term support
- •Resistance band intact
Stock is in a short-term downtrend over the last month, falling ~8.8% to $205.07 with immediate support at $205.07 and primary resistance at $230–$236, leaving scope for range-bound trading unless $205.07 breaks or $230–$236 is reclaimed.
Rapid drop from $227.68 to $205.07 in mid-March increased volatility and execution risk
Sentiment & News
Key News Insights:
- •Dividend growth
- •Pipeline momentum
- •J&J competition
AbbVie is drawing investor interest for strong dividend growth and pipeline-driven sales—backed by a $380M U.S. manufacturing expansion and neuroscience momentum—while J&J's oral IL‑23 approval poses competitive pressure.
Robust cash returns and R&D investment support upside, but Icotyde's approval could weigh on Skyrizi revenue and near‑term sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings